To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Ability to provide signed informed consent
Age 18-75 years at time of study entry
Willingness and ability to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Histology showing recurrent clear cell ovarian, peritoneal, or fallopian tube cancer (mixed histology with predominant clear cell component is acceptable).
Participation in another clinical study with an investigational product (IP) during the last 28 days.
Prior treatment with anti-CTLA-4 or anti-PDL-1/PD-1 antibodies.
Patients with mismatch repair deficient (dMMR) by IHC or microsatellite instability-high tumors
Concurrent treatment on another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Single group
Dostarlimab
DrugGiven by vein (IV)
LB-100
DrugGIven by vein (IV)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
